Glycolysis (Plasmodium species)

Glycolysis is the primary metabolic pathway for ATP production in Plasmodium species, particularly during the asexual blood stages. The parasite relies almost exclusively on glycolysis for energy, making it a validated drug target. Key components include the glucose transporter, glucokinase, and phosphofructokinase (PFK9). Many glycolytic enzymes are structurally distinct from their human counterparts, offering opportunities for selective drug design. Inhibiting key steps or transporters rapidly depletes ATP levels, impairing parasite growth or survival. Mathematical models help identify vulnerable steps for intervention. While no current antimalarial drugs directly target this metabolic route, ongoing research aims to identify selective inhibitors. Inhibition of glycolysis can contribute to clinical symptoms like lactic acidosis and hypoglycemia.

Other names

Plasmodium glycolysisGlycolytic pathway in PlasmodiumP. falciparum glycolysis

Inhibition of glycolytic enzymes or glucose transport, leading to ATP depletion and parasite death.